Tafamidis recommended for treating rare heart condition

Getty/PeopleImages

By Sarah Lowden

Patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) could now be eligible for treatment with tafamidis, after it was recommended for use on the NHS in England.

The National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending tafamidis (also called Vyndaqel and made by Pfizer) for patients with ATTR-CM.